

Notice Regarding Offer of Refunds to 340B Covered Entities for Purchases of RedHill Biopharma Products

May 22, 2024

RedHill Biopharma, Inc. (RedHill) has recalculated 340B ceiling prices for the NDCs listed below for the periods July 1, 2022, through September 30, 2022, (3Q2022) and October 1, 2022, through December 31, 2022 (4Q2022). As a result of the recalculated 340B Ceiling Prices, RedHill has determined that, pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4), a refund is owed to 340B Covered Entities that purchased these products during these time periods.

340B covered entities that purchased the impacted RedHill products during this timeframe will receive a credit effectuated through RedHill BioPharma as described below:

- 340B Covered Entities that are entitled to an aggregate refund across applicable NDCs of greater than or equal to \$15.00 will be contacted directly by, or on behalf of, RedHill with information on how the refund will be processed.
- The 340B Covered Entities that are entitled to an aggregate refund across all applicable NDCs of \$14.99 or less **will not be contacted directly, or on behalf of, Redhill**. Instead, RedHill is offering a refund to these 340B Covered Entities through this notice. If a 340B Covered Entity does not receive communication from, or on behalf of, RedHill and that 340B Covered Entity believes it is entitled to a refund on the applicable NDCs, then the 340B Covered Entity should contact RedHill at the following email address: 340BRefunds@redhillus.com to request the refund and accept RedHill's refund offer. RedHill will then work with the 340B Covered Entity to process any refund that is due to the 340B Covered Entity for the applicable NDCs

NDC	Description	Refund Period	Refund Period
57841-1150-02	Talicia DR 10mg/250mg/12.5mg	3Q 2022	
57841-1301-01	Movantik 25mg		4Q 2022
57841-1301-03	Movantik 25mg		4Q2022
57841-1300-01	Movantik 12.5mg		4Q2022
57841-1200-01	Aemcolo 194mg		4Q 2022

RedHill has asked the Health Resources and Services Administration (HRSA) to post this notice on the HRSA's public website to ensure transparency to all 340B Covered Entities

regarding the Ceiling Price recalculations for the products identified above and to offer a refund to any of the 340B Covered Entities that may have purchased the products identified above during the relevant time periods. Please direct any questions and/or request for additional information to RedHill at the following email address:

340BRefunds@redhillus.com